A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
for Extensive Stage-small Cell Lung Cancer
Drug: Atezolizumab
26 locations incl. Birmingham
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT06362252·Phase 1, Phase 2·Recruiting